Sharkey, Howes & Javer’s AstraZeneca AZN Stock Holding History

Sharkey, Howes & Javer’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12	Closed	-$1K	–	208
2017 Q1	$1K	Buy	+12	New	+$699	﹤0.01%	204

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Sharkey, Howes & Javer's AZN Position: Q2 2017 in Review

Sharkey, Howes & Javer sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 12 shares — an estimated $1K sold.

Sharkey, Howes & Javer first reported a position in AZN in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Sharkey, Howes & Javer reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
Sharkey, Howes & Javer sold 12 AstraZeneca shares in Q2 2017, an estimated $1K.
Sharkey, Howes & Javer first reported a position in AstraZeneca in Q1 2017 and held it in 1 quarter.
Sharkey, Howes & Javer's AstraZeneca position peaked at $1K in Q1 2017.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Sharkey, Howes & Javer's 13F filing for Q2 2017, filed 19 Jul 2017.